Condition
Recurrent Glioblastoma Multiforme (GBM)
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
66.7%
2 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 2 (1)
Trial Status
Terminated2
Enrolling By Invitation1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06616727Phase 1Enrolling By InvitationPrimary
The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM
NCT04782609Phase 1TerminatedPrimary
Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma
NCT00290771Phase 2TerminatedPrimary
Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)
Showing all 3 trials